152 related articles for article (PubMed ID: 30581389)
1. Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy.
Fazio C; Covre A; Cutaia O; Lofiego MF; Tunici P; Chiarucci C; Cannito S; Giacobini G; Lowder JN; Ferraldeschi R; Taverna P; Di Giacomo AM; Coral S; Maio M
Front Pharmacol; 2018; 9():1443. PubMed ID: 30581389
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches.
Lofiego MF; Piazzini F; Caruso FP; Marzani F; Solmonese L; Bello E; Celesti F; Costa MC; Noviello T; Mortarini R; Anichini A; Ceccarelli M; Coral S; Di Giacomo AM; Maio M; Covre A;
J Transl Med; 2024 Mar; 22(1):223. PubMed ID: 38429759
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy.
Lofiego MF; Cannito S; Fazio C; Piazzini F; Cutaia O; Solmonese L; Marzani F; Chiarucci C; Di Giacomo AM; Calabrò L; Coral S; Maio M; Covre A; On Behalf Of The EPigenetic Immune-Oncology Consortium Airc Epica Investigators
Epigenomes; 2021 Dec; 5(4):. PubMed ID: 34968251
[TBL] [Abstract][Full Text] [Related]
4. Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Wong KK; Hassan R; Yaacob NS
Front Oncol; 2021; 11():624742. PubMed ID: 33718188
[TBL] [Abstract][Full Text] [Related]
5. Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy.
Anichini A; Molla A; Nicolini G; Perotti VE; Sgambelluri F; Covre A; Fazio C; Lofiego MF; Di Giacomo AM; Coral S; Manca A; Sini MC; Pisano M; Noviello T; Caruso F; Brich S; Pruneri G; Maurichi A; Santinami M; Ceccarelli M; Palmieri G; Maio M; Mortarini R;
J Exp Clin Cancer Res; 2022 Nov; 41(1):325. PubMed ID: 36397155
[TBL] [Abstract][Full Text] [Related]
6. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications.
Fonsatti E; Nicolay HJ; Sigalotti L; Calabrò L; Pezzani L; Colizzi F; Altomonte M; Guidoboni M; Marincola FM; Maio M
Clin Cancer Res; 2007 Jun; 13(11):3333-8. PubMed ID: 17545540
[TBL] [Abstract][Full Text] [Related]
7. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
8. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR).
Coral S; Sigalotti L; Gasparollo A; Cattarossi I; Visintin A; Cattelan A; Altomonte M; Maio M
J Immunother; 1999 Jan; 22(1):16-24. PubMed ID: 9924695
[TBL] [Abstract][Full Text] [Related]
9. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models.
Covre A; Coral S; Nicolay H; Parisi G; Fazio C; Colizzi F; Fratta E; Di Giacomo AM; Sigalotti L; Natali PG; Maio M
Oncoimmunology; 2015 Aug; 4(8):e1019978. PubMed ID: 26405573
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications.
Coral S; Sigalotti L; Colizzi F; Spessotto A; Nardi G; Cortini E; Pezzani L; Fratta E; Fonsatti E; Di Giacomo AM; Nicotra MR; Natali PG; Altomonte M; Maio M
J Cell Physiol; 2006 Apr; 207(1):58-66. PubMed ID: 16252259
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma.
Jueliger S; Lyons J; Cannito S; Pata I; Pata P; Shkolnaya M; Lo Re O; Peyrou M; Villarroya F; Pazienza V; Rappa F; Cappello F; Azab M; Taverna P; Vinciguerra M
Epigenetics; 2016 Oct; 11(10):709-720. PubMed ID: 27646854
[TBL] [Abstract][Full Text] [Related]
13. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
[TBL] [Abstract][Full Text] [Related]
14. The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.
Wolff F; Leisch M; Greil R; Risch A; Pleyer L
Cell Commun Signal; 2017 Mar; 15(1):13. PubMed ID: 28359286
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
16. Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: identification of functional disparities between azacytidine and decitabine.
Hsieh YY; Huang TC; Lo HL; Jhan JY; Chen ST; Yang PM
Oncotarget; 2016 May; 7(19):27363-78. PubMed ID: 27036028
[TBL] [Abstract][Full Text] [Related]
17. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
[TBL] [Abstract][Full Text] [Related]
18. Reactivation of Silenced WT1 Transgene by Hypomethylating Agents - Implications for in vitro Modeling of Chemoimmunotherapy.
Kwon YR; Son MJ; Kim HJ; Kim YJ
Immune Netw; 2012 Apr; 12(2):58-65. PubMed ID: 22740791
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic remodelling of DNA in cancer.
Lettini AA; Guidoboni M; Fonsatti E; Anzalone L; Cortini E; Maio M
Histol Histopathol; 2007 Dec; 22(12):1413-24. PubMed ID: 17701921
[TBL] [Abstract][Full Text] [Related]
20. Novel prodrugs of decitabine with greater metabolic stability and less toxicity.
Hattori N; Sako M; Kimura K; Iida N; Takeshima H; Nakata Y; Kono Y; Ushijima T
Clin Epigenetics; 2019 Aug; 11(1):111. PubMed ID: 31370878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]